Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 16/20 | 0.37 |
| ▸ | MMP2 | P08253 | 14/20 | 0.37 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | MMP14 | P50281 | 8/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734507 | 1.00 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL13495285 | 1.00 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL735547 | 1.00 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL734508 | 1.00 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL734731 | 0.85 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL733934 | 0.85 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL733933 | 0.85 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL733932 | 0.85 | ADAMTS5 (0.37) | ADAMTS5MMP2MMP13MMP14ADAMTS4 | |
| SCHEMBL734398 | 0.85 | HTR1A (0.40) | ADAMTS5MMP2MAPT | |
| SCHEMBL734399 | 0.85 | HTR1A (0.40) | ADAMTS5MMP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | ADAMTS5 4707/4885MMP2 3027/4885MMP13 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.